0001062993-24-019774.txt : 20241127 0001062993-24-019774.hdr.sgml : 20241127 20241127170840 ACCESSION NUMBER: 0001062993-24-019774 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20241127 FILED AS OF DATE: 20241127 DATE AS OF CHANGE: 20241127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Luu Brendan CENTRAL INDEX KEY: 0001842369 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 241512322 MAIL ADDRESS: STREET 1: C/O ENANTA PHARMACEUTICALS, INC. STREET 2: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043205099 FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 4 KINGSBURY AVENUE CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 4 KINGSBURY AVENUE CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-11-27 0001177648 ENANTA PHARMACEUTICALS INC ENTA 0001842369 Luu Brendan C/O ENANTA PHARMACEUTICALS, INC. 4 KINGSBURY AVENUE WATERTOWN MA 02472 0 1 0 0 Chief Business Officer 0 Stock Option (right to buy) 8.83 2024-11-27 4 A 0 75000 0.00 A 2034-11-27 Common Stock 75000 75000 D Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024). Exhibit 24 Power of Attorney filed herewith. /s/ Matthew Kowalsky as attorney-in-fact 2024-11-27 EX-24.1 2 exhibit24-1.txt B. LUU POA POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Jay R. Luly, Paul J. Mellett, Matthew P. Kowalsky, Stacie Aarestad and Ryan Rourke Reed, or each of them acting individually, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned a Form ID application to be filed with the Securities and Exchange Commission to obtain EDGAR codes for the undersigned; (2) execute for and on behalf of the undersigned Forms 3, 4, and 5 with respect to the securities of Enanta Pharmaceuticals, Inc. (the "Company") in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID application or Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of July, 2024. By: /s/ Brendan Luu Print Name: Brendan Luu (Signature page to Section 16 Power of Attorney for Enanta)